Pub Date : 2024-04-30DOI: 10.1186/s44158-024-00165-3
Massimo Girardis, Irene Coloretti, Massimo Antonelli, Giorgio Berlot, Stefano Busani, Andrea Cortegiani, Gennaro De Pascale, Francesco Giuseppe De Rosa, Silvia De Rosa, Katia Donadello, Abele Donati, Francesco Forfori, Maddalena Giannella, Giacomo Grasselli, Giorgia Montrucchio, Alessandra Oliva, Daniela Pasero, Ornella Piazza, Stefano Romagnoli, Carlo Tascini, Bruno Viaggi, Mario Tumbarello, Pierluigi Viale
Background: In the last decades, several adjunctive treatments have been proposed to reduce mortality in septic shock patients. Unfortunately, mortality due to sepsis and septic shock remains elevated and NO trials evaluating adjunctive therapies were able to demonstrate any clear benefit. In light of the lack of evidence and conflicting results from previous studies, in this multidisciplinary consensus, the authors considered the rational, recent investigations and potential clinical benefits of targeted adjunctive therapies.
Methods: A panel of multidisciplinary experts defined clinical phenotypes, treatments and outcomes of greater interest in the field of adjunctive therapies for sepsis and septic shock. After an extensive systematic literature review, the appropriateness of each treatment for each clinical phenotype was determined using the modified RAND/UCLA appropriateness method.
Results: The consensus identified two distinct clinical phenotypes: patients with overwhelming shock and patients with immune paralysis. Six different adjunctive treatments were considered the most frequently used and promising: (i) corticosteroids, (ii) blood purification, (iii) immunoglobulins, (iv) granulocyte/monocyte colony-stimulating factor and (v) specific immune therapy (i.e. interferon-gamma, IL7 and AntiPD1). Agreement was achieved in 70% of the 25 clinical questions.
Conclusions: Although clinical evidence is lacking, adjunctive therapies are often employed in the treatment of sepsis. To address this gap in knowledge, a panel of national experts has provided a structured consensus on the appropriate use of these treatments in clinical practice.
{"title":"Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23.","authors":"Massimo Girardis, Irene Coloretti, Massimo Antonelli, Giorgio Berlot, Stefano Busani, Andrea Cortegiani, Gennaro De Pascale, Francesco Giuseppe De Rosa, Silvia De Rosa, Katia Donadello, Abele Donati, Francesco Forfori, Maddalena Giannella, Giacomo Grasselli, Giorgia Montrucchio, Alessandra Oliva, Daniela Pasero, Ornella Piazza, Stefano Romagnoli, Carlo Tascini, Bruno Viaggi, Mario Tumbarello, Pierluigi Viale","doi":"10.1186/s44158-024-00165-3","DOIUrl":"https://doi.org/10.1186/s44158-024-00165-3","url":null,"abstract":"<p><strong>Background: </strong>In the last decades, several adjunctive treatments have been proposed to reduce mortality in septic shock patients. Unfortunately, mortality due to sepsis and septic shock remains elevated and NO trials evaluating adjunctive therapies were able to demonstrate any clear benefit. In light of the lack of evidence and conflicting results from previous studies, in this multidisciplinary consensus, the authors considered the rational, recent investigations and potential clinical benefits of targeted adjunctive therapies.</p><p><strong>Methods: </strong>A panel of multidisciplinary experts defined clinical phenotypes, treatments and outcomes of greater interest in the field of adjunctive therapies for sepsis and septic shock. After an extensive systematic literature review, the appropriateness of each treatment for each clinical phenotype was determined using the modified RAND/UCLA appropriateness method.</p><p><strong>Results: </strong>The consensus identified two distinct clinical phenotypes: patients with overwhelming shock and patients with immune paralysis. Six different adjunctive treatments were considered the most frequently used and promising: (i) corticosteroids, (ii) blood purification, (iii) immunoglobulins, (iv) granulocyte/monocyte colony-stimulating factor and (v) specific immune therapy (i.e. interferon-gamma, IL7 and AntiPD1). Agreement was achieved in 70% of the 25 clinical questions.</p><p><strong>Conclusions: </strong>Although clinical evidence is lacking, adjunctive therapies are often employed in the treatment of sepsis. To address this gap in knowledge, a panel of national experts has provided a structured consensus on the appropriate use of these treatments in clinical practice.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"28"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11059820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-27DOI: 10.1186/s44158-024-00164-4
Daniela Pasero, Laura Pistidda, Davide Piredda, Corrado Liperi, Andrea Cossu, Raffaella Esposito, Angela Muroni, Cristiano Mereu, Carlino Rum, Gian Pietro Branca, Franco Mulas, Mariangela Puci, Giovanni Sotgiu, Pierpaolo Terragni
Background: Preliminary studies suggest that moderate ARDS and acute renal failure might benefit from extracorporeal CO2 removal (ECCO2R) coupled with CRRT. However, evidence is limited and potential for this coupled treatment may need to be explored. The aim of the present study was to evaluate whether a protective driving pressure was obtained applying low-flow ECCO2-R plus CRRT in patients affected by moderate ARDS with COVID-19 compared to an historical group without COVID-19.
Methods: A case-control study has been conducted comparing a group of consecutive moderate ARDS patients presenting AKI and affected by COVID-19, who needed low-flow ECCO2-R plus CRRT to achieve an ultra-protective ventilatory strategy, with historical group without COVID-19 that matched for clinical presentation and underwent the same ultra-protective treatment. VT was set at 6 mL/kg predicted body weight then ECCO2R was assessed to facilitate ultra-protective low VT ventilation to preserve safe Pplat and low driving pressure.
Results: ECCO2R+CRRT reduced the driving pressure from 17 (14-18) to 11.5 (10-15) cmH2O (p<0.0004) in the fourteen ARDS patients by decreasing VT from 6.7 ml/kg PBW (6.1-6.9) to 5.1 (4.2-5.6) after 1 hour (p <0.0001). In the ARDS patients with COVID-19, the driving pressure reduction was more effective from baseline 18 (14-24) cmH2O to 11 (10-15) cmH2O (p<0.004), compared to the control group from 15 (13-17) to 12(10-16) cmH2O (p< 0.03), after one hour. ECCO2R+CRRT did not affected 28 days mortality in the two groups, while we observed a shorter duration of mechanical ventilation (19 {7-29} vs 24 {22-38} days; p=0.24) and ICU length of stay (19 {7-29} vs 24 {22-78} days; p=0.25) in moderate ARDS patients with COVID-19 compared to control group.
Conclusions: In moderate ARDS patients with or without COVID-19 disease, ECCO2R+CRRT may be and effective supportive treatment to reach protective values of driving pressure unless severe oxygenation defects arise requiring ECMO therapy initiation.
{"title":"Lung (extracorporeal CO<sub>2</sub> removal) and renal (continuous renal replacement therapy) support: the role of ultraprotective strategy in Covid 19 and non-Covid 19 ARDS. A case-control study.","authors":"Daniela Pasero, Laura Pistidda, Davide Piredda, Corrado Liperi, Andrea Cossu, Raffaella Esposito, Angela Muroni, Cristiano Mereu, Carlino Rum, Gian Pietro Branca, Franco Mulas, Mariangela Puci, Giovanni Sotgiu, Pierpaolo Terragni","doi":"10.1186/s44158-024-00164-4","DOIUrl":"https://doi.org/10.1186/s44158-024-00164-4","url":null,"abstract":"<p><strong>Background: </strong>Preliminary studies suggest that moderate ARDS and acute renal failure might benefit from extracorporeal CO<sub>2</sub> removal (ECCO<sub>2</sub>R) coupled with CRRT. However, evidence is limited and potential for this coupled treatment may need to be explored. The aim of the present study was to evaluate whether a protective driving pressure was obtained applying low-flow ECCO<sub>2-</sub>R plus CRRT in patients affected by moderate ARDS with COVID-19 compared to an historical group without COVID-19.</p><p><strong>Methods: </strong>A case-control study has been conducted comparing a group of consecutive moderate ARDS patients presenting AKI and affected by COVID-19, who needed low-flow ECCO<sub>2-</sub>R plus CRRT to achieve an ultra-protective ventilatory strategy, with historical group without COVID-19 that matched for clinical presentation and underwent the same ultra-protective treatment. V<sub>T</sub> was set at 6 mL/kg predicted body weight then ECCO<sub>2</sub>R was assessed to facilitate ultra-protective low V<sub>T</sub> ventilation to preserve safe Pplat and low driving pressure.</p><p><strong>Results: </strong>ECCO<sub>2</sub>R+CRRT reduced the driving pressure from 17 (14-18) to 11.5 (10-15) cmH<sub>2</sub>O (p<0.0004) in the fourteen ARDS patients by decreasing V<sub>T</sub> from 6.7 ml/kg PBW (6.1-6.9) to 5.1 (4.2-5.6) after 1 hour (p <0.0001). In the ARDS patients with COVID-19, the driving pressure reduction was more effective from baseline 18 (14-24) cmH<sub>2</sub>O to 11 (10-15) cmH<sub>2</sub>O (p<0.004), compared to the control group from 15 (13-17) to 12(10-16) cmH<sub>2</sub>O (p< 0.03), after one hour. ECCO<sub>2</sub>R+CRRT did not affected 28 days mortality in the two groups, while we observed a shorter duration of mechanical ventilation (19 {7-29} vs 24 {22-38} days; p=0.24) and ICU length of stay (19 {7-29} vs 24 {22-78} days; p=0.25) in moderate ARDS patients with COVID-19 compared to control group.</p><p><strong>Conclusions: </strong>In moderate ARDS patients with or without COVID-19 disease, ECCO<sub>2</sub>R+CRRT may be and effective supportive treatment to reach protective values of driving pressure unless severe oxygenation defects arise requiring ECMO therapy initiation.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"27"},"PeriodicalIF":0.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11055375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-24DOI: 10.1186/s44158-024-00162-6
Muhammad Hudaib, Hurais Malik, Syeda Javeria Zakir, Samra Rabbani, Dhanushan Gnanendran, Abdul Rehman Shah Syed, Noor Fatima Suri, Javeria Khan, Arham Iqbal, Nowal Hussain, Muhammad Abdullah, Satesh Kumar, Mahima Khatri, Giustino Varrassi
{"title":"Correction: Efficacy and safety of ciprofol versus propofol for induction and maintenance of general anesthesia: a systematic review and meta-analysis.","authors":"Muhammad Hudaib, Hurais Malik, Syeda Javeria Zakir, Samra Rabbani, Dhanushan Gnanendran, Abdul Rehman Shah Syed, Noor Fatima Suri, Javeria Khan, Arham Iqbal, Nowal Hussain, Muhammad Abdullah, Satesh Kumar, Mahima Khatri, Giustino Varrassi","doi":"10.1186/s44158-024-00162-6","DOIUrl":"https://doi.org/10.1186/s44158-024-00162-6","url":null,"abstract":"","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"26"},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-11DOI: 10.1186/s44158-024-00160-8
Muhammad Hudaib, Hurais Malik, Syeda Javeria Zakir, Samra Rabbani, Dhanushan Gnanendran, Abdul Rehman Shah Syed, Noor Fatima Suri, Javeria Khan, Arham Iqbal, Nowal Hussain, Muhammad Abdullah, Satesh Kumar, Mahima Khatri, Giustino Varrassi
Background: Propofol has been the gold standard for anesthesia induction and maintenance due to its rapid onset and favorable pharmacokinetic properties. However, the search for alternative agents with improved safety and efficacy has led to the emergence of ciprofol (HSK3486), a structural analog of propofol. This systematic review and meta-analysis aim to comprehensively assess the safety and efficacy of ciprofol compared to propofol for anesthesia induction and maintenance in adult patients undergoing surgical procedures.
Methods: This study included only double-arm RCTs in which participants were aged eighteen or older undergoing surgery. For the statistical analysis of the extracted data, we employed RevMan 5.4.1.
Results: Ciprofol demonstrated a promising trend of higher anesthesiologists' satisfaction during the induction phase (MD 0.14, 95%, CI - 0.28 to 0.56, p = 0.51), whereas Propofol was favored during maintenance. Propofol also exhibited advantages with a shorter time to successful anesthesia induction (MD 0.08 min, 95% CI 0.00 to 0.15, p = 0.04), and quicker attainment of full alertness (MD 0.11 min, 95% CI - 1.29 to 1.52, p = 0.87), suggesting its efficiency in clinical practice. Importantly, there were no significant disparities in the success rate of anesthesia.
Conclusion: Both ciprofol and propofol demonstrate comparable efficacy and safety for anesthesia induction and maintenance in adult patients undergoing surgery. While propofol provides a faster onset of induction, ciprofol exhibits advantages in terms of pain management. Clinicians should consider these findings when selecting anesthetic agents, and tailoring choices to individual patient needs and clinical scenarios.
{"title":"Efficacy and safety of ciprofol versus propofol for induction and maintenance of general anesthesia: a systematic review and meta-analysis.","authors":"Muhammad Hudaib, Hurais Malik, Syeda Javeria Zakir, Samra Rabbani, Dhanushan Gnanendran, Abdul Rehman Shah Syed, Noor Fatima Suri, Javeria Khan, Arham Iqbal, Nowal Hussain, Muhammad Abdullah, Satesh Kumar, Mahima Khatri, Giustino Varrassi","doi":"10.1186/s44158-024-00160-8","DOIUrl":"https://doi.org/10.1186/s44158-024-00160-8","url":null,"abstract":"<p><strong>Background: </strong>Propofol has been the gold standard for anesthesia induction and maintenance due to its rapid onset and favorable pharmacokinetic properties. However, the search for alternative agents with improved safety and efficacy has led to the emergence of ciprofol (HSK3486), a structural analog of propofol. This systematic review and meta-analysis aim to comprehensively assess the safety and efficacy of ciprofol compared to propofol for anesthesia induction and maintenance in adult patients undergoing surgical procedures.</p><p><strong>Methods: </strong>This study included only double-arm RCTs in which participants were aged eighteen or older undergoing surgery. For the statistical analysis of the extracted data, we employed RevMan 5.4.1.</p><p><strong>Results: </strong>Ciprofol demonstrated a promising trend of higher anesthesiologists' satisfaction during the induction phase (MD 0.14, 95%, CI - 0.28 to 0.56, p = 0.51), whereas Propofol was favored during maintenance. Propofol also exhibited advantages with a shorter time to successful anesthesia induction (MD 0.08 min, 95% CI 0.00 to 0.15, p = 0.04), and quicker attainment of full alertness (MD 0.11 min, 95% CI - 1.29 to 1.52, p = 0.87), suggesting its efficiency in clinical practice. Importantly, there were no significant disparities in the success rate of anesthesia.</p><p><strong>Conclusion: </strong>Both ciprofol and propofol demonstrate comparable efficacy and safety for anesthesia induction and maintenance in adult patients undergoing surgery. While propofol provides a faster onset of induction, ciprofol exhibits advantages in terms of pain management. Clinicians should consider these findings when selecting anesthetic agents, and tailoring choices to individual patient needs and clinical scenarios.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-08DOI: 10.1186/s44158-024-00159-1
Jessica M Currò, Cristina Santonocito, Federica Merola, Simone Messina, Marco Sanfilippo, Serena Brancati, Filippo Drago, Filippo Sanfilippo
Background: Propofol is the most commonly used hypnotic agent used during sedation and general anesthesia (GA) practice, offering faster recovery compared to benzodiazepines. However, cardiovascular impact of propofol and pain at injection are commonly encountered side effects. Ciprofol is a novel disubstituted phenol derivative, and there is growing evidence regarding its clinical use.
Methods: We conducted a systematic literature search (updated on 23 July 2023) to evaluate safety and efficacy of ciprofol in comparison to propofol in patients undergoing procedures under sedation or GA. We focused on randomized controlled trials (RCTs) only, extrapolating data on onset and offset, and on the side effects and the pain at injection.
Results: The search revealed 14 RCTs, all conducted in China. Eight RCTs studied patients undergoing sedation, and six focused on GA. Bolus of ciprofol for sedation or induction of GA varied from 0.2 to 0.5 mg/kg. In four studies using ciprofol for maintenance of GA, it was 0.8-2.4 mg/kg/h. Ciprofol pharmacokinetics seemed characterized by slower onset and offset as compared to propofol. Pain during injection was less frequent in the ciprofol group in all the 13 studies reporting it. Eight studies reported "adverse events" as a pooled outcome, and in five cases, the incidence was higher in the propofol group, not different in the remaining ones. Occurrence of hypotension was the most commonly investigated side effects, and it seemed less frequent with ciprofol.
Conclusion: Ciprofol for sedation or GA may be safer than propofol, though its pharmacokinetics may be less advantageous.
{"title":"Ciprofol as compared to propofol for sedation and general anesthesia: a systematic review of randomized controlled trials.","authors":"Jessica M Currò, Cristina Santonocito, Federica Merola, Simone Messina, Marco Sanfilippo, Serena Brancati, Filippo Drago, Filippo Sanfilippo","doi":"10.1186/s44158-024-00159-1","DOIUrl":"https://doi.org/10.1186/s44158-024-00159-1","url":null,"abstract":"<p><strong>Background: </strong>Propofol is the most commonly used hypnotic agent used during sedation and general anesthesia (GA) practice, offering faster recovery compared to benzodiazepines. However, cardiovascular impact of propofol and pain at injection are commonly encountered side effects. Ciprofol is a novel disubstituted phenol derivative, and there is growing evidence regarding its clinical use.</p><p><strong>Methods: </strong>We conducted a systematic literature search (updated on 23 July 2023) to evaluate safety and efficacy of ciprofol in comparison to propofol in patients undergoing procedures under sedation or GA. We focused on randomized controlled trials (RCTs) only, extrapolating data on onset and offset, and on the side effects and the pain at injection.</p><p><strong>Results: </strong>The search revealed 14 RCTs, all conducted in China. Eight RCTs studied patients undergoing sedation, and six focused on GA. Bolus of ciprofol for sedation or induction of GA varied from 0.2 to 0.5 mg/kg. In four studies using ciprofol for maintenance of GA, it was 0.8-2.4 mg/kg/h. Ciprofol pharmacokinetics seemed characterized by slower onset and offset as compared to propofol. Pain during injection was less frequent in the ciprofol group in all the 13 studies reporting it. Eight studies reported \"adverse events\" as a pooled outcome, and in five cases, the incidence was higher in the propofol group, not different in the remaining ones. Occurrence of hypotension was the most commonly investigated side effects, and it seemed less frequent with ciprofol.</p><p><strong>Conclusion: </strong>Ciprofol for sedation or GA may be safer than propofol, though its pharmacokinetics may be less advantageous.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11000282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-03DOI: 10.1186/s44158-024-00158-2
Ken Tonai, Shinshu Katayama, Kansuke Koyama, Hisashi Imahase, Shin Nunomiya
Background: Sepsis-3 emphasizes the recognition of sepsis-induced cellular metabolic abnormalities, and utilizes serum lactate level as a biomarker of cellular metabolic abnormalities. Magnesium plays an important role as a cofactor in glucose metabolism, although it is not well known that magnesium deficiency causes elevated serum lactate levels. Additionally, it remains unclear how magnesium status affects the role of serum lactate levels as a marker of metabolic abnormalities in sepsis. Thus, this study aimed to investigate the association between serum magnesium and lactate levels in patients with sepsis and explore this relationship from the perspectives of time course and circulatory abnormalities.
Methods: This retrospective observational study of adult patients with sepsis was performed at the 16-bed intensive care unit of Jichi Medical University Hospital between June 2011 and December 2017. The relationship between serum magnesium and lactate levels for 5 days from intensive care unit admission was investigated along the time course. Multivariate logistic regression analysis was performed to evaluate the association between serum magnesium and lactate levels during intensive care unit admission.
Results: Among 759 patients included, 105 had hypomagnesemia (magnesium level < 1.6 mg/dL), 558 had normal serum magnesium levels (1.6-2.4 mg/dL), and 96 had hypermagnesemia (magnesium level > 2.4 mg/dL) at intensive care unit admission. From intensive care unit admission to day 5, the hypomagnesemia group had higher serum lactate levels and a higher frequency of lactic acidosis than the normal magnesium level and hypermagnesemia groups (70% vs. 51.6% vs. 50%; P < 0.001). Hypomagnesemia at intensive care unit admission was independently associated with lactic acidosis, i.e., lactic acid level > 2 mmol/L (odds ratio, 2.76; 95% confidence interval, 1.60-4.76; P < 0.001).
Conclusions: Hypomagnesemia was associated with serum lactate levels in the early and post-resuscitation phases of sepsis. Further studies are needed to elucidate whether the magnesium status is associated with sepsis-induced cellular and metabolic abnormalities.
背景:败血症-3 强调识别败血症引起的细胞代谢异常,并将血清乳酸水平作为细胞代谢异常的生物标志物。镁作为辅助因子在葡萄糖代谢中发挥着重要作用,但目前还不清楚缺镁会导致血清乳酸盐水平升高。此外,镁的状态如何影响血清乳酸水平作为败血症代谢异常标志物的作用,目前仍不清楚。因此,本研究旨在调查脓毒症患者血清镁和乳酸水平之间的关系,并从时间进程和循环异常的角度探讨这种关系:这项回顾性观察研究于2011年6月至2017年12月期间在吉大医科大学附属医院16张病床的重症监护室进行,对象为成年败血症患者。研究人员调查了重症监护室入院 5 天内血清镁和乳酸水平之间的关系。对重症监护室入院期间血清镁和乳酸水平之间的关系进行了多变量逻辑回归分析:结果:在纳入的 759 名患者中,有 105 人在入住重症监护室时患有低镁血症(镁水平为 2.4 mg/dL)。与镁水平正常组和高镁血症组相比(70% vs. 51.6% vs. 50%;P 2 mmol/L(几率比,2.76;95% 置信区间,1.60-4.76;P 结论:低镁血症与乳酸酸中毒有关:低镁血症与败血症早期和复苏后阶段的血清乳酸水平有关。需要进一步的研究来阐明镁的状态是否与败血症引起的细胞和代谢异常有关。
{"title":"Association between hypomagnesemia and serum lactate levels in patients with sepsis: a retrospective observational study.","authors":"Ken Tonai, Shinshu Katayama, Kansuke Koyama, Hisashi Imahase, Shin Nunomiya","doi":"10.1186/s44158-024-00158-2","DOIUrl":"https://doi.org/10.1186/s44158-024-00158-2","url":null,"abstract":"<p><strong>Background: </strong>Sepsis-3 emphasizes the recognition of sepsis-induced cellular metabolic abnormalities, and utilizes serum lactate level as a biomarker of cellular metabolic abnormalities. Magnesium plays an important role as a cofactor in glucose metabolism, although it is not well known that magnesium deficiency causes elevated serum lactate levels. Additionally, it remains unclear how magnesium status affects the role of serum lactate levels as a marker of metabolic abnormalities in sepsis. Thus, this study aimed to investigate the association between serum magnesium and lactate levels in patients with sepsis and explore this relationship from the perspectives of time course and circulatory abnormalities.</p><p><strong>Methods: </strong>This retrospective observational study of adult patients with sepsis was performed at the 16-bed intensive care unit of Jichi Medical University Hospital between June 2011 and December 2017. The relationship between serum magnesium and lactate levels for 5 days from intensive care unit admission was investigated along the time course. Multivariate logistic regression analysis was performed to evaluate the association between serum magnesium and lactate levels during intensive care unit admission.</p><p><strong>Results: </strong>Among 759 patients included, 105 had hypomagnesemia (magnesium level < 1.6 mg/dL), 558 had normal serum magnesium levels (1.6-2.4 mg/dL), and 96 had hypermagnesemia (magnesium level > 2.4 mg/dL) at intensive care unit admission. From intensive care unit admission to day 5, the hypomagnesemia group had higher serum lactate levels and a higher frequency of lactic acidosis than the normal magnesium level and hypermagnesemia groups (70% vs. 51.6% vs. 50%; P < 0.001). Hypomagnesemia at intensive care unit admission was independently associated with lactic acidosis, i.e., lactic acid level > 2 mmol/L (odds ratio, 2.76; 95% confidence interval, 1.60-4.76; P < 0.001).</p><p><strong>Conclusions: </strong>Hypomagnesemia was associated with serum lactate levels in the early and post-resuscitation phases of sepsis. Further studies are needed to elucidate whether the magnesium status is associated with sepsis-induced cellular and metabolic abnormalities.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-19DOI: 10.1186/s44158-024-00156-4
Giulia Bongiorno, Helena Biancuzzi, Francesca Dal Mas, Rym Bednarova, Alessandro Vittori, Luca Miceli
The work described below explores the field of the effects of pulsed radiofrequency for pain relief purposes. While the effects of this technique on pain modulation (A-delta and C fibers) are relatively well-known, little has been written yet about the potential of pulsed radiofrequency interactions with other fibers. The proposed algorithm, specifically elaborated, investigates the effect of this technique on neuromuscular fatigue, through a surface electromyographic study of the femoral nerve of a patient with residual pain after knee arthroplasty surgery, before and after the treatment. This work yields a preliminary result that is encouraging for subsequent large-scale studies.
下文描述的工作探索了脉冲射频在缓解疼痛方面的作用。虽然这种技术对疼痛调制(A-德尔塔纤维和 C 纤维)的影响相对众所周知,但关于脉冲射频与其他纤维相互作用的潜力却鲜有论述。所提出的算法是通过对一名膝关节置换术后残余疼痛患者的股神经进行治疗前后的表面肌电图研究,具体阐述了这一技术对神经肌肉疲劳的影响。这项工作取得了初步成果,对后续的大规模研究具有鼓舞作用。
{"title":"Pulsed radiofrequency on peripheral nerve as a rehabilitation aid.","authors":"Giulia Bongiorno, Helena Biancuzzi, Francesca Dal Mas, Rym Bednarova, Alessandro Vittori, Luca Miceli","doi":"10.1186/s44158-024-00156-4","DOIUrl":"10.1186/s44158-024-00156-4","url":null,"abstract":"<p><p>The work described below explores the field of the effects of pulsed radiofrequency for pain relief purposes. While the effects of this technique on pain modulation (A-delta and C fibers) are relatively well-known, little has been written yet about the potential of pulsed radiofrequency interactions with other fibers. The proposed algorithm, specifically elaborated, investigates the effect of this technique on neuromuscular fatigue, through a surface electromyographic study of the femoral nerve of a patient with residual pain after knee arthroplasty surgery, before and after the treatment. This work yields a preliminary result that is encouraging for subsequent large-scale studies.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-19DOI: 10.1186/s44158-024-00157-3
Andrea Cortegiani, Denise Battaglini, Giovanna Amato, Astrid Ursula Behr, Katia Donadello, Sharon Einav, Maria Grazia Frigo, Giorgio Fullin, Alberto Giannini, Mariachiara Ippolito, Franco Marozzi, Roberta Monzani, Gianpaola Monti, Marcus J Schultz, Vito Torrano, Gianluca Villa, Antonino Giarratano
Background: Dissemination of medical practice and scientific information through social media (SoMe) by clinicians and researchers is increasing. Broad exposure of information can promote connectivity within the scientific community, overcome barriers to access to sources, increase debate, and reveal layperson perspectives and preferences. On the other hand, practices lacking scientific evidence may also be promoted, laypeople may misunderstand the professional message, and clinician may suffer erosion of professional status. The aim of this project was to enhance awareness and advise the anesthesia community and clinicians at large about the potential risks advocate for responsible use of SoMe to disseminate information related to medical practices and knowledge.
Methods: A modified Delphi process with prespecified consensus criteria was conducted among a multidisciplinary panel of experts, including anesthesiologists-intensivists, clinical psychologists, and forensic medicine specialists. Six items were identified: Ethics and deontological principles, the practice of sharing information via social media, legal aspects, psychological aspects, self-promotion, and criteria for appropriate dissemination. Statements and rationales were produced and subjected to blinded panelists' votes. After reaching consensus, a document was written which then underwent external review by experts uninvolved in the consensus process. The project was promoted by the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care (SIAARTI).
Results: Twelve statements were produced, and consensus was achieved for all. The panel concluded that the general principles guiding dissemination of professional information via SoMe must remain in line with the general principles of ethics, deontology, and scientific validity that guide the medical profession and science in general. Professional equity must be maintained while communicating via SoMe. Medical practices lacking support by scientific evidence should not be disseminated. Patients' informed consent must be obtained before dissemination of information, images, or data. Self-promotion must not be prioritized over any of these principles.
Conclusions: When sharing medical practices and scientific information on SoMe, healthcare professionals are advised to act conscientiously and ethically. Local regulations should be adhered to. Institutional training on the potential risks and proper of SoMe for such purpose may contribute to preservation of professional integrity.
背景:临床医生和研究人员通过社交媒体(SoMe)传播医疗实践和科学信息的情况日益增多。信息的广泛传播可以促进科学界的联系,克服获取信息来源的障碍,增加辩论,并揭示非专业人士的观点和偏好。另一方面,缺乏科学依据的做法也可能得到推广,非专业人士可能会误解专业信息,临床医生的专业地位也可能受到削弱。本项目旨在提高麻醉界和广大临床医生对SoMe潜在风险的认识和建议,倡导负责任地使用SoMe传播与医疗实践和知识相关的信息:在一个多学科专家小组(包括麻醉师、麻醉师、临床心理学家和法医专家)中开展了一个经过修改的德尔菲过程,该过程采用了预先规定的共识标准。确定了六个项目:道德和伦理原则、通过社交媒体分享信息的做法、法律方面、心理方面、自我宣传以及适当传播的标准。编写了声明和理由,并由盲人小组成员进行投票。在达成共识后,编写了一份文件,然后由未参与共识过程的专家进行外部审查。该项目由意大利麻醉镇痛复苏和重症监护学会(SIAARTI)推动:结果:共产生了 12 份声明,并就所有声明达成了共识。小组得出的结论是,通过 SoMe 传播专业信息的一般指导原则必须与指导医学界和整个科学界的道德、道义和科学有效性等一般原则保持一致。在通过 SoMe 进行交流时,必须保持职业公平。不得传播缺乏科学证据支持的医疗实践。在传播信息、图像或数据之前,必须征得患者的知情同意。自我宣传不得优先于上述任何原则:建议医疗保健专业人员在 SoMe 上分享医疗实践和科学信息时,应自觉遵守道德规范。应遵守当地法规。就SoMe的潜在风险和使用SoMe的适当性进行机构培训,可有助于维护职业操守。
{"title":"Dissemination of clinical and scientific practice through social media: a SIAARTI consensus-based document.","authors":"Andrea Cortegiani, Denise Battaglini, Giovanna Amato, Astrid Ursula Behr, Katia Donadello, Sharon Einav, Maria Grazia Frigo, Giorgio Fullin, Alberto Giannini, Mariachiara Ippolito, Franco Marozzi, Roberta Monzani, Gianpaola Monti, Marcus J Schultz, Vito Torrano, Gianluca Villa, Antonino Giarratano","doi":"10.1186/s44158-024-00157-3","DOIUrl":"https://doi.org/10.1186/s44158-024-00157-3","url":null,"abstract":"<p><strong>Background: </strong>Dissemination of medical practice and scientific information through social media (SoMe) by clinicians and researchers is increasing. Broad exposure of information can promote connectivity within the scientific community, overcome barriers to access to sources, increase debate, and reveal layperson perspectives and preferences. On the other hand, practices lacking scientific evidence may also be promoted, laypeople may misunderstand the professional message, and clinician may suffer erosion of professional status. The aim of this project was to enhance awareness and advise the anesthesia community and clinicians at large about the potential risks advocate for responsible use of SoMe to disseminate information related to medical practices and knowledge.</p><p><strong>Methods: </strong>A modified Delphi process with prespecified consensus criteria was conducted among a multidisciplinary panel of experts, including anesthesiologists-intensivists, clinical psychologists, and forensic medicine specialists. Six items were identified: Ethics and deontological principles, the practice of sharing information via social media, legal aspects, psychological aspects, self-promotion, and criteria for appropriate dissemination. Statements and rationales were produced and subjected to blinded panelists' votes. After reaching consensus, a document was written which then underwent external review by experts uninvolved in the consensus process. The project was promoted by the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care (SIAARTI).</p><p><strong>Results: </strong>Twelve statements were produced, and consensus was achieved for all. The panel concluded that the general principles guiding dissemination of professional information via SoMe must remain in line with the general principles of ethics, deontology, and scientific validity that guide the medical profession and science in general. Professional equity must be maintained while communicating via SoMe. Medical practices lacking support by scientific evidence should not be disseminated. Patients' informed consent must be obtained before dissemination of information, images, or data. Self-promotion must not be prioritized over any of these principles.</p><p><strong>Conclusions: </strong>When sharing medical practices and scientific information on SoMe, healthcare professionals are advised to act conscientiously and ethically. Local regulations should be adhered to. Institutional training on the potential risks and proper of SoMe for such purpose may contribute to preservation of professional integrity.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-11DOI: 10.1186/s44158-024-00155-5
Paolo Capuano, Giuseppe Sepolvere, Antonio Toscano, Paolo Scimia, Simona Silvetti, Mario Tedesco, Luca Gentili, Gennaro Martucci, Gaetano Burgio
In recent years, there has been a growing awareness of the limitations and risks associated with the overreliance on opioids in various surgical procedures, including cardiothoracic surgery.This shift on pain management toward reducing reliance on opioids, together with need to improve patient outcomes, alleviate suffering, gain early mobilization after surgery, reduce hospital stay, and improve patient satisfaction and functional recovery, has led to the development and widespread implementation of enhanced recovery after surgery (ERAS) protocols.In this context, fascial plane blocks are emerging as part of a multimodal analgesic in cardiac surgery and as alternatives to conventional neuraxial blocks for thoracic surgery, and there is a growing body of evidence suggesting their effectiveness and safety in providing pain relief for these procedures. In this review, we discuss the most common fascial plane block techniques used in the field of cardiothoracic surgery, offering a comprehensive overview of regional anesthesia techniques and presenting the latest evidence on the use of chest wall plane blocks specifically in this surgical setting.
{"title":"Fascial plane blocks for cardiothoracic surgery: a narrative review.","authors":"Paolo Capuano, Giuseppe Sepolvere, Antonio Toscano, Paolo Scimia, Simona Silvetti, Mario Tedesco, Luca Gentili, Gennaro Martucci, Gaetano Burgio","doi":"10.1186/s44158-024-00155-5","DOIUrl":"10.1186/s44158-024-00155-5","url":null,"abstract":"<p><p>In recent years, there has been a growing awareness of the limitations and risks associated with the overreliance on opioids in various surgical procedures, including cardiothoracic surgery.This shift on pain management toward reducing reliance on opioids, together with need to improve patient outcomes, alleviate suffering, gain early mobilization after surgery, reduce hospital stay, and improve patient satisfaction and functional recovery, has led to the development and widespread implementation of enhanced recovery after surgery (ERAS) protocols.In this context, fascial plane blocks are emerging as part of a multimodal analgesic in cardiac surgery and as alternatives to conventional neuraxial blocks for thoracic surgery, and there is a growing body of evidence suggesting their effectiveness and safety in providing pain relief for these procedures. In this review, we discuss the most common fascial plane block techniques used in the field of cardiothoracic surgery, offering a comprehensive overview of regional anesthesia techniques and presenting the latest evidence on the use of chest wall plane blocks specifically in this surgical setting.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.1186/s44158-024-00154-6
Valentina Bellini, Marco Brambilla, Elena Bignami
Perioperative medicine is undergoing many changes with the introduction of new technologies. Wearable devices are among them. These novel tools are providing an additional possibility for perioperative monitoring. However, in order to ensure that the introduction of wearable device in surgical wards does not lead to additional challenges for healthcare professionals, a careful implementation plan should be drawn up by a multidisciplinary team. In addition, a chain of liability should also be established a priori to facilitate their use and avoid ambiguity in the occurrence of a critical event.
{"title":"Wearable devices for postoperative monitoring in surgical ward and the chain of liability.","authors":"Valentina Bellini, Marco Brambilla, Elena Bignami","doi":"10.1186/s44158-024-00154-6","DOIUrl":"10.1186/s44158-024-00154-6","url":null,"abstract":"<p><p>Perioperative medicine is undergoing many changes with the introduction of new technologies. Wearable devices are among them. These novel tools are providing an additional possibility for perioperative monitoring. However, in order to ensure that the introduction of wearable device in surgical wards does not lead to additional challenges for healthcare professionals, a careful implementation plan should be drawn up by a multidisciplinary team. In addition, a chain of liability should also be established a priori to facilitate their use and avoid ambiguity in the occurrence of a critical event.</p>","PeriodicalId":73597,"journal":{"name":"Journal of Anesthesia, Analgesia and Critical Care (Online)","volume":"4 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140061467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}